ALUMIS INC.
ALUMIS INC. (ALMS): 9 pipeline candidates · 1 upcoming catalyst · ~7 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
7.1 months
D/E 0.18
Lead: Phase 3
9 candidates
1 upcoming, next in ~867d
7 buys · 0 sells (180d)
A transparent, data-derived signal for ALUMIS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.8B
Cash
$65.3M
Quarterly Burn
$87.1M
Runway
7.1 mo
Revenue
$1.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| A-005 | Phase 1 |
| blinded envudeucitinib | Phase 3 |
| Blinded ESK-001 | Phase 3 |
| envudeucitinib | Phase 3 |
| ESK-001 | Phase 3 |
| IRF5 program | Preclinical |
| lonigutamab | Phase 1/Phase 2 |
| open-label envudeucitinib | Phase 3 |
| Open-Label ESK-001 | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
194
Total value held
$1.79B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 8,064,532 | $177.7M |
| blackrock, inc. | 7,170,868 | $158.0M |
| deep track capital, lp | 6,772,595 | $149.2M |
| samsara biocapital, llc | 6,345,219 | $139.8M |
| janus henderson group plc | 4,219,816 | $92.9M |
| saturn v capital management lp | 3,202,075 | $70.5M |
| ubs group ag | 3,054,865 | $67.3M |
| octagon capital advisors lp | 2,830,700 | $62.4M |
| mpm bioimpact llc | 2,386,529 | $52.6M |
| baker bros. advisors lp | 2,012,500 | $44.3M |
Showing top 10 of 194 institutional holders of ALUMIS INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ALUMIS INC.'s pipeline?
ALUMIS INC. (ALMS) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ALUMIS INC.'s lead drug candidate?
ALUMIS INC.'s most advanced tracked candidate is A-005 (Phase 1) for Healthy Volunteer.
What is ALUMIS INC.'s next catalyst?
ALUMIS INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Sa" — expected November 1, 2028.
What is ALUMIS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ALUMIS INC. has approximately 7.1 months of cash runway.
What is ALUMIS INC.'s market capitalization?
ALUMIS INC.'s market capitalization is approximately $2.8B.
Get the full picture on ALUMIS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.